ATEC
Spine surgery, but make it a growth story
Alphatec Holdings turned in second-quarter 2026 results for the period ended June 30th, 2026, and the headline is pretty straightforward: sales came in at $214 million while gross margin stayed sturdy at 72.2% on a GAAP basis and 72.5% non-GAAP.
For a spine-focused medtech company, that’s the kind of number set that tells you the business is still pushing for scale rather than just waving around a cool product deck. The real investor question is whether revenue growth is outrunning the cost structure — because in medtech, operating leverage is the difference between “promising” and “please stop burning cash.”
The part investors will actually squint at
Alphatec also said GAAP operating expenses were $156 million and non-GAAP operating expenses were $135 million. That’s the stuff that matters if you’re trying to figure out whether the company is finally getting closer to the awkward but magical phase where growth starts paying rent.
What to watch next:
- whether revenue keeps climbing in the back half of the year
- whether margins keep holding up instead of doing a dramatic faceplant
- whether operating expenses start behaving like a grown-up company’s expenses
Big picture
This is the classic medtech tightrope: grow fast enough to matter, but not so expensively that investors need a stress ball. If Alphatec can keep scaling revenue while tightening the expense belt, the stock story gets a lot more interesting.